All In Biotech

Drug Trial Radar · NCT02777008

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTP-543 in Healthy Subjects

A Two-Part Single Center, Randomized, Sequential, Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CTP-543 in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Mar 13, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

77

Actual

Start

May 2016

Primary completion

Dec 2016

Study completion Mar 2017

Sponsor

Lead sponsor
Concert PharmaceuticalsIndustry
Sponsor type
Industry
First posted
May 19, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Basic science
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Single- and multiple-ascending dose study of CTP-543 in healthy volunteers.

Conditions

  • Healthy

Interventions

  • CTP-543Drug

  • Placebo for CTP-543Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events as a Measure of Safety and TolerabilityTime frame: 24 hours
  2. Measurement of CTP-543 exposure in plasma under fasted conditionsTime frame: 24 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Adelaide, South Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.